0001096906-24-000489.txt : 20240318 0001096906-24-000489.hdr.sgml : 20240318 20240318175110 ACCESSION NUMBER: 0001096906-24-000489 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231228 FILED AS OF DATE: 20240318 DATE AS OF CHANGE: 20240318 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Chinoporos Constantine CENTRAL INDEX KEY: 0002014509 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38898 FILM NUMBER: 24760350 MAIL ADDRESS: STREET 1: C/O APPLIED THERAPEUTICS, INC. STREET 2: 545 FIFTH AVENUE, SUITE 1400 CITY: NEW YORK STATE: NY ZIP: 10017 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Applied Therapeutics, Inc. CENTRAL INDEX KEY: 0001697532 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 545 FIFTH AVENUE, SUITE 1400 CITY: NEW YORK STATE: NY ZIP: 10017 BUSINESS PHONE: 212-220-9226 MAIL ADDRESS: STREET 1: 545 FIFTH AVENUE, SUITE 1400 CITY: NEW YORK STATE: NY ZIP: 10017 FORMER COMPANY: FORMER CONFORMED NAME: Applied Therapeutics Inc. DATE OF NAME CHANGE: 20170208 4 1 form4.xml PRIMARY DOCUMENT X0508 4 2023-12-28 0 0001697532 Applied Therapeutics, Inc. APLT 0002014509 Chinoporos Constantine C/O APPLIED THERAPEUTICS, INC. 545 FIFTH AVENUE, SUITE 1400 NEW YORK NY 10017 0 1 0 0 See Remarks 0 Common Stock 2023-12-28 4 A 0 300000.0000 0.0000 A 300000.0000 D Consists of compensatory Restricted Stock Units granted under Applied Therapeutics, Inc.'s 2019 Equity Incentive Plan (the "Plan"). Each compensatory Restricted Stock Unit represents a contingent right to receive one share of the issuer's common stock. One-fourth (1/4th) of the compensatory Restricted Stock Units shall vest on December 28, 2024, and one thirty-sixth (1/36th) of the remaining shares subject to the compensatory Restricted Stock Units shall vest each month thereafter, subject to the reporting person continuing to provide services through each such date. Chief Operating Officer and Chief Business Officer /s/ Shoshana Shendelman, as attorney-in-fact 2024-03-18